Fangzhou Inc.
方舟云康控股有限公司
(A company incorporated in the Cayman Islands with limited liability)
(Stock code: 6086)

ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"). The board (the "**Board**") of directors of Fangzhou Inc. (the "**Company**") has noted the recent increases in the price of the shares of the Company (the "**Shares**") on the Stock Exchange on September 12, 2025.

The Board has also noted that the Company published press releases (the "**Press Releases**") relating to its 10th H2H Healthcare Ecosystem Conference, held on September 10, 2025, which contained certain Company updates, including (i) the launch of the Company's proprietary "XingShi" Large Language Model ("**XS LLM**") that serves as the foundation for five of its flagship applications (AI Medication Finder, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI-Powered Search), enabling advanced clinical decision support and personalized chronic disease management; (ii) the strategic partnership with Innovent Biologics ("**Innovent**") to integrate Fangzhou's H2H digital health ecosystem with Innovent's pipeline of weight-management therapies, initially leveraging the Company's XS LLM to deliver personalized digital care and adherence support for Innovent's mazdutide, enhancing patient outcomes in China's rapidly growing weight-management market; and (iii) the strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. ("**Otsuka**") to jointly develop comprehensive digital solutions encompassing medication support services, targeted patient outreach programs, and health education initiatives, by combining the Company's AI technology strengths with Otsuka's innovative drug portfolio.

After having made such enquiry with respect to the Company as is reasonable in the circumstances, the Board confirms that (i) the information contained in the Press Releases does not constitute inside information for the purpose of Rule 13.09(2) of the Listing Rules or the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); and (ii) it is not aware of any reason for the increase in the trading price of the Shares or of any information which must be announced to avoid a false market in the Shares or of any inside information that needs to be disclosed.

Shareholders of the Company and prospective investors are advised to exercise caution when dealing in the Shares.

This announcement is made by the order of the Company. The Board collectively and individually accepts responsibility for the accuracy of this announcement.

By order of the Board
Fangzhou Inc.
Mr. XIE Fangmin
Chairman

Hong Kong, September 14, 2025

As of the date of this announcement, the Board comprises Mr. XIE Fangmin, Mr. ZHOU Feng and Mr. ZOU Yuming as executive Directors, Mr. David McKee HAND as non-executive Directors, and Dr. WANG Haizhong, Ms. KANG Wei and Mr. ZHU Xiaolu as independent non-executive Directors.